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ABSTRACT
The topoisomerase I (TOP1) inhibitor irinotecan trig-
gers cell death by trapping TOP1 on DNA, generating
cytotoxic protein-linked DNA breaks (PDBs). Despite
its wide application in a variety of solid tumors, the
mechanisms of cancer cell resistance to irinotecan
remains poorly understood. Here, we generated col-
orectal cancer (CRC) cell models for irinotecan re-
sistance and report that resistance is neither due to
downregulation of the main cellular target of irinote-
can TOP1 nor upregulation of the key TOP1 PDB re-
pair factor TDP1. Instead, the faster repair of PDBs
underlies resistance, which is associated with per-
turbed histone H4K16 acetylation. Subsequent treat-
ment of irinotecan-resistant, but not parental, CRC
cells with histone deacetylase (HDAC) inhibitors can
effectively overcome resistance. Immunohistochem-
ical analyses of CRC tissues further corroborate the
importance of histone H4K16 acetylation in CRC. Fi-
nally, the resistant clones exhibit cross-resistance
with oxaliplatin but not with ionising radiation or
5-fluoruracil, suggesting that the latter two could
be employed following loss of irinotecan response.
These findings identify perturbed chromatin acetyla-
tion in irinotecan resistance and establish HDAC in-
hibitors as potential therapeutic means to overcome
resistance.
INTRODUCTION
Irinotecan is converted into its active form SN-38, which
is a camptothecin (CPT)-based agent that promotes can-
cer cell death by interfering with the topoisomerase type
1 enzyme (TOP1) (1). TOP1 is involved in DNA relax-
ation to promote cellular activities such as transcription
and DNA replication (2,3). Whilst DNA cleavage and re-
ligation by TOP1 is a fast process, TOP1 poisons pre-
vent the re-ligation of reversible TOP1 cleavage complexes
(TOP1cc), resulting in covalently trapped TOP1 protein-
linked DNA breaks (PDBs) (3–6). PDBs are irreversible
and removal of TOP1 by proteasomal degradation is re-
quired for subsequent repair. Upon TOP1 degradation, ty-
rosyl DNA phosphodiesterase 1 (TDP1) processes the re-
maining 3′-phospho-tyrosyl peptide in a PARP1-dependent
manner prior to repair completion by the DNA single-
strand break repair pathway (SSBR) (7–12). Indeed, the
majority of TOP1-PDBs are repaired in this way (13–15).
If an advancing replication fork encounters a TOP1cc or an
unrepaired TOP1-PDB on the leading strand, the forks are
reversed and stabilised by PARP1 to allow time for the re-
moval of TOP1-PDBs (16), a process that is negatively reg-
ulated through the RecQ1 helicase (17,18). Failure to repair
TOP1-PDBs at replication forks ultimately results in repli-
cation run-off and the generation of a DNA double-strand
break (DSB) (19,20). DNADSBs trigger the DNA damage
response, including cell cycle arrest mediated by both ATM
and ATR, H2AX signalling and p53-regulated apoptosis
(6,21,22). TOP1 can also be removed from TOP1-PDBs by
nucleolytic cleavage of DNA, removing TOP1 and a stretch
of DNA towhich it is attached. This is conducted by a num-
ber of nucleases including the Mus81-Eme1 heterodimer
bound to the scaffold protein SLX4 that additionally car-
ries SLX1 (23–25). The XPF-ERCC1 endonuclease is also
implicated in TOP1 removal in an SLX4 independent man-
ner (24,26). Once excised, the remaining DSB is repaired
through homologous recombination (HR)-mediated DSB
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repair involving both the DNA damage response complex
MRN and the end processing factor CtIP (27–29). Persis-
tence of unrepaired PDBs and the generation of DSBs un-
derlie the clinical utility of TOP1 poisons as anti-cancer
drugs.
Despite their broad application in the clinic, resistance to
TOP1 poisons remains an unmet clinical challenge. Recent
studies have focused on identifying molecular biomarkers
for predicting irinotecan sensitivity (30,31). Classical mech-
anisms for loss of sensitivity such as loss of drug conver-
sion to its active metabolite or gain of drug pump functions
have been reported (32,33). Inhibition of the ABCG2 drug
efflux pump using sorafenib was shown to sensitise both
non-resistant and irinotecan resistant CRC cells to irinote-
can (34). The inability to trigger cell cycle arrest (G2/M ar-
rest) and p53-mediated apoptosis in response to CPT can
also promote loss of CPT sensitivity (35). TOP1 downreg-
ulation and inactivating mutations that reduce the trapping
of TOP1 onDNAhave also been reported as possiblemech-
anisms of CPT resistance (35,36). Finally, hyperactivity of
factors of the aforementioned SSBR and HR DNA repair
pathways may also account for resistance onset to TOP1
poisons. For example, upregulation in the level or activity
of TDP1, CtIP, XPF-ERCC1 and Mus81-Eme1 is known
to protect cells from CPT-mediated damage (35,37–39). Al-
though much is known about changes in bona fideDNA re-
pair factors as modulators of CPT response, little is known
about the role of epigenetics, particularly chromatin acety-
lation in this process.
Here, we generated CRC models of irinotecan (CPT-11)
resistance derived from two independent cell lines to inves-
tigate the mechanism of resistance onset, cross-resistance
with other CRC targeting therapies and novel means by
which to overcome resistance. Our findings reveal that
irinotecan resistance is neither due to modulation of the
main cellular target of irinotecan, TOP1, nor upregulation
of the key TOP1 repair factor, TDP1. Instead, we reveal that
the faster repair of PDBs and the improved ability to re-
start irinotecan-arrested forks are the driver of resistance.
Changes in bona fide PDB repair proteins are not driv-
ing resistance but instead perturbations in histone H4K16
acetylation and rate of 53BP1 recruitment to damage sites
is the underlying mechanism of resistance. Consequently,
histone deacetylase inhibitors can mechanistically reverse
resistance. Finally, we identify cross-resistance with oxali-
platin but not with ionising radiation or 5-fluoruracil, sug-
gesting that the latter two could be employed following loss
of irinotecan response.
MATERIALS AND METHODS
Cells and reagents
The human colorectal cancer cell lines RKO and DLD1
(ATCC, LGC Standards, Middlesex, UK) and their CPT-
11 resistant derivative single clones were maintained in a
5% CO2 incubator at 37◦C and grown in Gibco RPMI
media (Life Technologies, Paisley, UK) supplemented with
10% FCS and 2 mM L-glutamine. Irinotecan hydrochlo-
ride (CPT-11), 5-fluorouracil (5-FU), oxaliplatin, hydrox-
yurea (HU), camptothecin (CPT), doxorubicin, etoposide
and SN-38were obtained fromSigma-Aldrich (Gillingham,
UK) whilst the PARP inhibitor, olaparib (AZD2281) was
obtained from Stratech Scientific Limited (Suffolk, UK).
Trichostatin A (TSA) and Panobinostat (LBH-589) were
obtained from Selleckchem.
Generation of irinotecan resistant clones
RKOandDLD1 cells weremaintained inRPMI (10%FCS,
2 mM L-glutamine) media supplemented with either a daily
low dose of CPT-11 (0.1 M, treatment culture 1), daily
moderate CPT-11 dose (0.5 M, treatment culture 2), daily
CPT-11 dose that increased at every split (0.1, 0.2, 0.3 M,
etc. up till 1 M, treatment culture 3) or a high CPT-11
dose (1 M increasing to 2 M, treatment culture 4) that
was repeated post-recovery. Splits were carried out twice a
week and recovery lasted ∼7 days whilst the treatment pe-
riod spanned 2 months. Selection of single clones was car-
ried out in a 96-well format using 2 MCPT-11 and surviv-
ing single colonies were expanded, stored andmaintained in
CPT-11-free media for further analysis.
Clonogenic survival assay
Cell sensitivity to irinotecan (CPT-11), camptothecin
(CPT), oxaliplatin, 5-fluorouracil (5-FU), hydroxyurea
(HU), olaparib, SN-38, doxorubicin, etoposide, trichostatin
A (TSA), panobinostat (LBH-589) and irradiation was
measured by clonogenic survival assay.Adhered cells seeded
at dose dependent densities in 6 or 10 cm dishes were treated
with irradiation or media containing drug for the dura-
tion of colony formation (9 days). Colonies were subse-
quently fixed and stained using 0.4% methylene blue so-
lution in 50% methanol or 1% Giemsa in methanol and
the colonies containing >50 cells were counted as surviving
colonies. The surviving fraction was calculated as (colonies
counted/total cells seeded)treated/(colonies counted/total
cells seeded)untreated).
mRNA silencing
mRNA silencing was carried out using Lipofectamine
2000 or 3000 RNAiMAX reagent (Invitrogen, Paisley,
UK) as described previously (37). Briefly, a mixture of
10 l Lipofectamine 2000 RNAiMAX reagent in 250 l
FCS-free media was incubated at room temperature for 5
min prior to mixing with 250 l FCS-free media containing
siRNA oligonucleotides for TDP1 (ON-TARGETplus
smartpool, Fisher Scientific, Loughborough, UK),
RECQ1 (5′-GAAGAUUAUUGCACACUUUUUtt-
3′), PARP-1 (5′-AGAUAGAGCGUGAAGGCGAtt-
3′, 5′-AAGAUAGAGCGUGAAGGCGAAtt-3′),
MUS81 (5′-CAGCCCUGGUGGAUCGAUAtt-3′, 5′-
CAGGAGCCAUCAAGAAUAAtt-3′), XFP/ERCC4
(5′-CCAAACAGCUUUAUGAUUUtt-3′, 5′-GCACCU
CGAUGUUUAUAAAtt-3′, 5′-CGGAAGAAAUUAAG
CAUGAtt-3′, 5′-UGACAAGGGUACUACAUGAtt-
3′), CtIP (5′-GCUAAAACAGGAACGAAUCUUtt-3′),
KU70/XRCC6 (5′-UUCUCUUGGUAACUUUCCCtt-
3′), or the BLAST validated scrambled siRNA se-
quence (5′-UUCUUCGAACGUGUCACGUtt-3′) or
(5′-GCGCGCUUUGUAGGAUUCGtt-3′). The mixture
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was incubated for 20 min and added dropwise onto dishes
containing 3 × 105 cells in 3 ml media. A second transfec-
tion was carried out 6 or 24 h later, media replaced 24 h
after the first transfection and cells subjected to survival
assays and qPCR analyses.
Quantitative PCR
Cells were harvested for RNA extraction according to
the manufacturer instructions (RNeasy Mini Kit, Qia-
gen). Reverse transcription was conducted from the re-
spective mRNA transcripts using High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). Max-
ima SYBR Green 2X (Thermo Scientific) was added
to the cDNA-primer mix and qPCR performed us-
ing the following primers: PARP-1 (F: 5′-CCAACT
ACTGCCATACGTCTCA-3′ ; R: TTAGCTGAAGGA
TCAGGGGTAG), XPF/ERCC4 (F: 5′-GGGCATTGAC
ATTGAACCCG-3′; R: 5′-CTGTAGAGGCGGCCGTTA
TT-3′), CtIP (F: 5′-GAGCACTCTGTGTGTGCAAATG-
3′; R: 5′-GTTCCATGTG CTTTGGCCATTG-3′), SLX4
(F: 5′-GGAACTGGATAGGTTTGGAGTC-3′; R: CTGC
AACAGCGGCTGTGAGGAC-3′), GAPDH (F: 5′-TT
CGTCATGGGTGTGAACCA-3′; R: TGATGGCATG
GACTGTGGTC-3′) and KU70 (F: 5′-TCTTGGCTGT
GGTGTTCTATGGT-3′; R: 5′-GAGTGAGTAGTCAG
ATCCGTGGC-3′). Fold changes were calculated using
the following formula: Fold change = 2−CT, where
C = [CT(target,untreated) −CT(GAPDH,untreated)]
− [CT(target,treated) − CT(GAPDH,treated)] (40).
Whole cell extract
Adhered cells were washed twice with ice cold PBS (phos-
phate buffered saline), collected by centrifugation at 1500
rpm for 5 min and extraction carried out for 30 min us-
ing ice-cold lysis buffer (20 mM Tris–HCl pH 7.5, 10 mM
EDTA pH 8.0, 100 mM NaCl, 1% Triton X-100) supple-
mented with Complete Mini EDTA-free Protease Inhibitor
Cocktail (Roche Applied Science, Burgess Hill, UK). The
lysate was cleared by centrifugation at 13 000 rpm for 10min
and the supernatant collected as whole cell extract (WCE).
Bradford assay was used to measure protein concentration
and the samples stored at −80◦C.
Western blotting
WCE (40 g) was separated by 10% SDS-polyacrylamide
gel electrophoresis (PAGE) at 125 V for 2 h and trans-
ferred onto a Hybond-C Extra Nitrocellulose membrane
(Fisher Scientific UK, Loughborough, UK) at 25 V for 90
min. The membrane was blocked in 5% PBS-milk for 1 h
and probed overnight with 5% PBST-milk containing an-
tibodies against TDP1 (ab4166; Abcam, Cambridge, UK),
TOP1 (SC-32736; Santa Cruz Biotechnologies, California,
USA), PARP1 and cleaved PARP1 (A6.4.12, Biorad,Hemel
Hempstead, UK), pP53-pSER15 (#9284, Cell Signalling
Technology, Leiden, Netherlands), p21 (SC417; Santa Cruz
Biotechnologies, California, USA), Mus81 (ab14387, Ab-
cam, Cambridge, UK), RecQ1 (H-110; sc-25547; Santa
Cruz), RPA (LS-C 38952, Lifespan biosciences), BRCA2
(H-300, SC-8326, Santa Cruz), Rad51 (H-92 SC-8349,
Santa Cruz), histone H4K16Ac (#61529, Active Motif,
Belgium), histone H3K9Ac (ab4441, Abcam, Cambridge,
UK), histone H3K56Ac (#39281, Active Motif, Belgium),
histone H3K14Ac (#39599, Active Motif, Belgium) and
actin (A4700; Sigma-Aldrich, Gillingham, UK), TDP2
(AP33010-P050, Aviva Systems Biology), MRP4 (ab56675,
Abcam), XPF (Ab-1 (219), Rad17 (H3, SantaCruz), pATM
S1981 (Abcam), ATM (D2E2, Cell Signaling). Membranes
were washed in PBST three times prior to a 1 h incuba-
tion with HRP-labelled polyclonal goat anti-rabbit or poly-
clonal rabbit anti-mouse secondary antibodies (Dako, Ely,
UK) at a 1:3000 dilution in 5% PBST-milk. Membranes
were then washed in PBST three times prior to film devel-
opment using the SuperSignalWest PicoChemiluminescent
Substrate (Fisher Scientific UK, Loughborough, UK) and
band quantification using ImageJ software.
TDP1 activity assay
In vitro 3′-tyrosyl-DNA phosphodiesterase activity was
measured as previously described (37). Briefly, 10 l reac-
tion volumes containing 50 nM 5′-Cy5.5 labelled substrate
(5′-(Cy5.5)GATCTAAAAGACT(pY)-3′) (Midland Certi-
fied Reagent Company, Texas, USA) and the indicated
amounts of WCE (ng) or recombinant human TDP1 (7)
in assay buffer (25 mM HEPES, pH 8.0, 130 mM KCl, 1
mM DTT) were incubated at 37◦C for 1 h. Reaction prod-
ucts were mixed with 10 L loading buffer (44% deionized
formamide, 2.25 mM Tris-borate, 0.05 mM EDTA, 0.01%
xylene cyanol, 1% bromophenol blue), heated to 90◦C for
10 min and separated on a 20%Urea SequaGel (Fisher Sci-
entific, Loughborough, UK) at 190 V for 2 h in 1× TBE. A
FujiFilm Fluor Imager FLA-5100 was used to take images
at 635 nm and bands quantified using ImageJ software.
Immunostaining
Cells grown to sub-confluent densities on coverslips were
treated with DMSO, CPT-11 (1, 2 or 5 M) or 0.5 mM
hydroxyurea in media at 37◦C for 1.5 h. Coverslips were
washed twice with PBS and recovered in drug-free me-
dia for indicated time points. Coverslips were subsequently
washed twice in ice-cold PBS prior to fixing with 3.7%
paraformaldehyde for 10 min and permeabilising in 0.2%
Triton-X in PBS for 3 min. Coverslips were washed three
times in PBS, blocked in 2% BSA-Fraction V (Sigma-
Aldrich, Gillingham, UK) for 30 min and incubated with
primary antibodies against H2AX (JBW301, Millipore,
Watford, UK), Rad51 (H-92, Santa Cruz Biotechnologies,
California, USA), pRPA (A300-245A, Bethyl Laborato-
ries, Texas, USA) and 53BP1 (A300-272A, Bethyl Labo-
ratories, Texas, USA) at dilutions of 1:800, 1:300, 1:200
and 1:400 in 2% BSA-Fraction V, respectively. Coverslips
were again thrice washed in PBS prior to incubation with
FITC-labelled anti-mouse or Cy3-labeled anti-rabbit sec-
ondary antibodies (Sigma-Aldrich, Gillingham, UK) at a
1:300 dilution in 2% BSA-Fraction V for 45 min. Cover-
slips were then washed three times in PBS and mounted us-
ing DAPI Vectashield (Vector Laboratories, Peterborough,
UK). Cells were visualised on a Nikon Eclipse e-400 mi-
croscope and the number of foci per cell was counted. For
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olaparib and TSA treatment, cells were pre-incubated with
1 M olaparib or 1 M TSA for 1 and 2 h, respectively,
prior to further drug treatment. Recovery was carried out
in media containing 1 M olaparib or 1 M TSA.
Measurement of TOP1 cleavage complexes (TOP1cc): mod-
ified alkaline COMET assay
The modified alkaline COMET assay (MACA) was modi-
fied from (41) and performed as described (22) to measure
TOP1-cleavage complexes (Top1-ccs). Cells suspended in
media (1× 105 in 1ml) were pre-treatedwith 10MMG132
for 2 h, followed by co-treatment with DMSO or CPT-
11 (15 or 30 M) for 1 h. The mix was subsequently cen-
trifuged at 1500 rpm and re-suspended in PBS containing
10MMG132, 400g/ml proteinase K (both from Sigma-
Aldrich, Gillingham, UK) and DMSO or CPT-11 (15 or 30
M). Cell suspension was subsequently mixed with 1.2%
Type VII low-melt agarose warmed to 42◦C (1:1 ratio) and
the mix immediately layered onto frosted glass slides pre-
coated with 0.6% agarose. Once set, the slides were incu-
bated in lysis solution (pH 10; 400 g/ml proteinase K, 10
MMG132, CPT-11 (15 or 30 M), 10 mMTris–HCl, 100
mM EDTA pH 8.0, 1% Triton X-100, 1% DMSO) at 37◦C
for 3 h. Slides were then submerged in electrophoresis buffer
(50 mMNaOH, 1mMEDTA, 1%DMSO) for 45 min to al-
low for DNA unwinding prior to DNA separation by elec-
trophoresis at 12 V for 25 min. On completion, slides were
immersed in neutralisation buffer (0.4 M Tris–HCl; pH 7)
for at least 1 h prior to staining with Sybr-Green diluted
1:10 000 in PBS for 10 min. Tail moment measurements for
100 cells per sample were obtained using the Comet Assay
IV software (Perceptive Instruments, UK).
Measurement of TOP1cc: CsCl fractionation and im-
munoblotting
TOP1 protein–DNA complexes (TOP1cc) were purified us-
ing caesium chloride density gradients. Cells (2 × 106) were
lysed in 1% sarcosyl, 8 M guanidine HCl, 30 mM Tris
pH 7.5 and 10 mM EDTA. Cell lysates were incubated at
70◦C for 15 min to remove all non-covalently bound pro-
teins from DNA. Cell lysates were then loaded on a cae-
sium chloride density (CsCl) step gradient (5 ml total vol-
ume) and centrifuged at 75 600 × g at 25◦C for 24 h to
separate free proteins from DNA. Ten consecutive 0.5 ml
fractions were collected and slot blotted onto Hybond-C
membrane (Amersham). To ensure equal DNA loading, the
DNA concentration in each extract was determined fluori-
metrically using PicoGreen (Molecular Probes/Invitrogen).
Covalent TOP1–DNA complexes were then detected by im-
munoblotting with anti-TOP1 antibodies (sc-32736, Santa
Cruz) and visualised by chemiluminescence. Fractions en-
riched for TOP1cc were pooled and subjected to serial di-
lution followed by band quantifications using the BioRad
ChemiDoc platform.
Cell cycle analysis
Fluorescence-activated cell sorting (FACS) analysis was
used to determine cell cycle profiles. Sub-confluent mono-
layer cells were treated continuously with CPT-11 and col-
lected at 24, 48 and 72 h post-treatment by trypsinisation,
washed twice in ice-cold PBS and 4× 106 cells re-suspended
in 0.5 ml PBS. The suspension was gently vortexed for 10 s
to ensure separation of aggregated cells and added slowly
to 4.5 ml ice-cold 70% ethanol for cell fixation, carried out
at 4◦C for at least 1 h and up to 48 h for the earliest time-
point. Cells were washed once in PBS and re-suspended in
1 ml PI staining solution to contain 0.1% Triton X-100, 10
g/ml propidium iodide (Molecular Probes, Paisley, UK),
100 g/ml RNase A (Sigma-Aldrich, Gillingham, UK).
Cells were stained in the dark for 30 min at room temper-
ature prior to cell sorting on the BD FACSCANTO sys-
tem (BD Biosciences, Oxford, UK) and analysis using FCS
Express 4 Flow software version 4.07.0011 (De Novo Soft-
ware, Glendale, USA).
DNA fibre assay
Exponentially growing cells were pulse-labelled with 25M
CldU (Sigma) for 20 min followed by 250 M IdU (Sigma)
for 30 min to quantify replication fork speed. Cells were
pulse-labeled with 25 M CldU for 10 min followed by
30 min treatment with 50 M CPT-11 (Sigma) then pulse-
labelled with 250 M IdU for 1 h to quantify replication
fork structures. Cells were then washed and resuspended
in cold PBS and diluted to ≈500 000 cell/ml. Each sam-
ple was spread onmultipleMenzel-Glaser Superfrost slides,
fixed, and stored at 4◦C. Samples were then incubated in
blocking solution (PBS + 1% BSA + 0.1% Tween-20) for
45 min followed by acid denaturation using 2.5 M HCl.
Slides were stained with a mixture of Rat anti-BrdU (1:500;
clone BU1/75; AbD Serotec) targeting CldU and Mouse
anti-BrdU (1:500; clone B44; Becton Dickinson) targeting
IdU. Cells were fixed using 4% paraformaldehyde andDNA
fibres visualized by staining with Alexafluor 488 donkey
anti-Rat and Alexafluor 555 goat anti-Mouse (Molecular
Probes) secondary antibodies. Finally, slides were mounted
in Fluoroshield (Sigma) and stored at −20◦C. DNA fi-
bres were examined using Olympus BX53 fluorescence up-
right microscope. Lengths of the fibres were measured,
and speeds of the forks were determined using speed =
length (Kb) / time (min). At least 238 fork structures were
counted per sample where green-red signals represent on-
going forks, green only represent stalled forks, and red only
represent new origin firing.
CellTiter-blue viability assay
Irinotecan sensitivity was determined using the CellTiter-
Blue cell viability assay (Promega, Southampton, UK).
Cells were seeded in triplicate at 3000 cells per well of a
96-well plate in irinotecan-containing media (0–20 M).
The plates were incubated at 37◦C for 4 days prior to
analysis with the CellTiter-Blue reagent. 20 l reagent
was added to each well, the plates incubated at 37◦C for
1.5 h and fluorescence intensity data collected using the
GloMax Multi Detection System (Promega, Southamp-
tion, UK) at excitation and emission wavelengths of ex
560 nm and em 590 nm. Growth fraction was calcu-
lated using background-subtracted readings as: (fluores-
cence readtreated/fluorescence readuntreated).
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Microarray expression profiling
The RNeasy mini RNA purification kit (Qiagen, Manch-
ester, UK) was used to purify mRNA from the RKO
parental cell line and the irinotecan-resistant clones
RSC316 and RSC526 according to the manufacturers de-
tails. ThemRNAquality was verified bymeasuring 260/280
and 260/230 ratios using a Nanodrop (Wilmington, USA).
The mRNA samples were subsequently sent to Cam-
bridge Genomic Services (CGS, Cambridge, UK) for ad-
ditional quality control prior to microarray analysis us-
ing a HumanHT-12 v4 WG-GX Beadchip on the Illumina
BeadArray system. The data was returned in the format X
and the real-fold change in mRNA levels calculated using
the equation 2X.
Sister chromatid exchange
Exponentially growing cells were either mock-treated or
treated with 1 M CPT-11 for 1 h at 37◦C. Cells were then
washed twice with PBS and incubated in CPT-free media
supplemented with 20 M 5-bromodeoxyuridine (BrdU)
for two cell generations (∼44 h). The mitotic inhibitor, col-
cemid (0.08g/ml) was then added to the media and 1 h
later, cells were pelleted and incubated in hypotonic solu-
tion of 37.5 mM KCl for 5 min at 37◦C. Cells were fixed by
dropwise addition of Carnoy’s solution (methanol: acetic
acid; 3:1 v/v) and incubated at −20◦C for 16–24 h. Cells
were then spread on cold wet slides that were pre-soaked in
double distilled water containing Decon 90 for 2 days, and
metaphase spreads were left to dry and aged at room tem-
perature for 3 days. Slides were incubated in Hoechst 33258
for 12 min at room temperature in the dark, washed twice
with distilled water, immersed in SSC buffer (2MNaCl, 0.3
M tri-sodium citrate, pH 7), and exposed to 365 nm UV
light for 15 min. Slides were subsequently incubated in SSC
buffer for 60 min at 60◦C and stained with 10% Giemsa
solution in 0.05 M phosphate buffer pH 6.8. At least 40
metaphase spreads were scored for SCEs by Olympus BX51
microscope.
Immunohistochemistry
A commercially available colon cancer tissue microar-
ray (TMA) (Abcam, Cambridge, UK; catalogue number
ab178133) was used to perform immunohistochemistry
(IHC) as previously described (42). This TMA comprises
96 samples from 48 cases including primary (n = 48) and
metastatic colorectal carcinoma (n= 36) in addition to nor-
mal human colon tissue (n= 12), which served as a positive
control along with sections from a transitional cell carci-
noma (TCC); the latter was obtained from the histopathol-
ogy department archive. Tissue sections were deparaffinised
in xylene and dehydrated in 100% ethanol followed by incu-
bation in 3% methanolic H2O2 for 20 min to block endoge-
nous peroxidase. Antigen retrieval was carried out by incu-
bating the slides in buffer comprising 1 mM EDTA, 0.05%
Tween20 and 1000 ml distilled water (pH 9.0) for 20 min at
95◦C. Slides were washed in PBS, blocked with serum for 30
min and incubated with a rabbit monoclonal antibody for
Histone H4K16ac (Abcam, catalogue number ab109463) at
4◦C overnight in a humidified container (1:100 dilution).
Omission of the primary antibody served as negative con-
trol. After overnight incubation, unbound primary anti-
bodywaswashed off. AVectastain Elite kit was used for sec-
ondary antibody and Avidin–Biotin Complex (ABC) at RT
in accordance with the manufacturer’s instructions (Vector
laboratories, Burlingame, USA). Secondary antibody was
added for 30 min followed by a wash and incubation with
ABC for another 30 min. 3,3′-diaminobenzidine (DAB)
(Vector laboratories) was used to stain slides for 2 min and
colouring reaction stopped using distilled water. Slides were
counterstained with haematoxylin, dehydrated in graded al-
cohols and mounted using DPXmounting media and glass
cover slips. Staining was considered positive when a brown
nuclear reaction was observed. IHC staining was quantified
using ImageJ software (version 1.49, NIH, USA) (43) and
the IHC profiler plugin which is a recently developed and
validated open source tool (44). Staining intensity and per-
centage positivity in each sample was obtained and a paired
Student’s t-test used to determine the statistical significance
between normal, primary and metastatic carcinoma in ad-
dition to comparison between different tumour grades. A
P-value of <0.05 was considered significant.
RESULTS
Drug resistance is an unmet clinical challenge hindering the
success of camptothecin-based treatments such as irinote-
can (CPT-11). To examine the mechanism of irinotecan
resistance in colorectal cancer (CRC), we generated resis-
tance models using two colorectal cancer cell lines, RKO
and DLD1. RKO was previously shown to be sensitive to
irinotecan whereas DLD1 was identified as relatively re-
sistant (37). Cells were cultured in media containing vary-
ing concentrations of irinotecan (single dose and dose es-
calation) over a period of two months. Irinotecan-resistant
clones were subsequently challenged with high irinotecan
dose on single cell dilutions, followed by picking and ex-
pansion of surviving single colonies (Figure 1A). Once es-
tablished, clones were grown andmaintained in media lack-
ing irinotecan, thereby enabling the study of resistance us-
ing the parental cell lines as controls. Using a clonogenic
survival assay, all selected clones were confirmed to be
irinotecan-resistant despite similar growth rates (Supple-
mentary Figure S1A) and either fell into two distinct sub-
populations or displayed a variation in the degree of ac-
quired resistance (Figure 1B and C).
Irinotecan is often combined with other treatments in the
clinic for colorectal cancer treatment such as radiation ther-
apy or 5-fluorouracil (5-FU). Irinotecan-based treatment
regimens are frequently replacedwith oxaliplatin-based reg-
imens when resistance emerges. We therefore first exam-
ined whether resistance to irinotecan also imparts resis-
tance to others. Irinotecan-resistant clones were subjected
to survival assays following exposure to  -irradiation, ox-
aliplatin, 5-FU, SN-38 or camptothecin (CPT). A similar
degree of resistance was observed following SN-38 or CPT
treatment, consistent with their function as TOP1 poisons,
ruling out differences in irinotecan conversion to its ac-
tive form, SN38, as the cause of resistance (Figure 1D and
E). In contrast, resistance was not observed following  -
irradiation or 5-FU (Figure 1F and G). However, all four
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Figure 1. Irinotecan-resistant colorectal cancer cells are resistant to oxaliplatin but not to 5-fluorouracil or ionising radiation. (A) RKO and DLD1 cells
were continuously treated with irinotecan (CPT-11) at a daily low dose (culture flask 1), daily moderate dose (culture flask 2), daily dose that increased
at every split (culture flask 3) or a high dose that was repeated post-recovery (culture flask 4/5). After approximately 2 months, single cell dilution and
CPT-11 selection was carried out to identify single CPT-11 resistant clones (first number represents flask of origin) that were stored and cultured in media
lacking CPT-11 for further experimentation. Selected CPT-11 resistant clones derived from the parental RKO (B) and DLD1 (C) cell lines were seeded
at low density and treated continuously with either 1 or 2 M CPT-11 for the duration of colony formation (7–12 days). Colonies were fixed, stained,
counted and the surviving fraction calculated as the surviving colony fractiontreated/surviving colony fractionuntreated where surviving colony fraction =
colonies counted/total cells seeded. Results are the average of 3 independent biological replicates ± STD. A survival assay was similarly carried out
following camptothecin treatment (D), SN-38 (E), exposure to ionising radiation (F), 5-fluorouracil treatment (G) and oxaliplatin treatment (H). Data are
the average of three independent biological replicates ± STD.
clones displayed a similar degree of resistance to oxaliplatin
as they did to irinotecan (Figure 1H). These experiments
suggest that cross-resistance occurs between irinotecan and
oxaliplatin but not between irinotecan and  -irradiation or
5-FU.
TDP1 and TOP1 levels are key determinants of irinote-
can response in colorectal cancer cells and TDP1 depletion
has been shown to sensitise the RKO cell line to irinote-
can by increasing the number of cytotoxic DSBs (37,45).
We therefore examined if TDP1 depletion could re-sensitise
CRC resistant clones to irinotecan. TDP1 was depleted
from three separate resistant clones using a pool of four
siRNA sequences followed by irinotecan clonogenic sur-
vival assays. In a marked contrast to the parental RKO
cells, for which we previously reported irinotecan sensitisa-
tion upon TDP1 depletion (37 and Supplementary Figure
S1B), irinotecan-resistant cells were also resistant to TDP1
depletion (Figure 2A–C, upper panels). These observations
were further confirmed in two additional resistant clones
(Supplementary Figure S1C). The lack of sensitisation was
not due to inefficient TDP1 depletion since the product of
TDP1 catalytic activity was readily detectable in an in vitro
assay from lysates of cells treated with scrambled siRNA
but not with TDP1 siRNA (Figure 2A–C, lower panels and
Supplementary Figure S1C and S1D). We conclude from
these experiments that TDP1 manipulation is unlikely to be
effective in overcoming irinotecan resistance in CRC.
Next, we examined whether TDP1 and TOP1 levels or
activity were altered. Western blotting of whole cell extracts
revealed no detectable gain of TDP1 or loss of TOP1 expres-
sion between parental and resistant clones (Supplementary
Figure S2A and S2B). We assessed TOP1 function by mea-
suring the products of TOP1 activity (TOP1cc) that accu-
mulate following CPT-11 treatment using the modified al-
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Figure 2. PARP1/TDP1 axis does not underpin irinotecan resistance in CRC cells. Irinotecan-resistant RSC2120 (A, upper panel), RSC316 (B, upper
panel) and RSC526 (C, upper panel) were treated with a scrambled siRNA or a pool of four TDP1 siRNA sequences followed by treatment with the
indicated concentrations of irinotecan. Survival was calculated from three biological replicates ± STD. Lysates prepared from the corresponding TDP1-
depleted cells were subjected to a TDP1 activity assay and reaction products separated by 20% denaturing PAGE (A–C, lower panels). The substrate (3′PY)
and product (3′P) are indicated for one representative experiment of three. (D) Parental RKO and RKO derived irinotecan-resistant cells were treated with
irinotecan for 1 h and TOP1 cleavage complexes (TOP1cc) quantified by the modified alkaline comet assay. The average tail moment of three biological
replicates is shown± STD for 100 cells measured per sample. (E) Cells were treated with irinotecan and TOP1cc purified by CsCl fractionation followed by
immunoblotting using anti TOP1 antibodies. CsCl fractions enriched with TOP1cc (fractions 4–7) are shown from a representative experiment (top) and
the average intensity of TOP1cc ± STD from three biological replicates is shown (bottom). (F) Whole cell extract prepared from RKO derived irinotecan
resistant clones were incubated with oligonucleotides harbouring a 3′-phosphotyrosine modification (3′PY) and 5′-fluorophore to monitor TDP1 catalytic
activity. Reaction products were separated by 20% denaturing PAGE and imaged using a FujiFilm Fluor Imager FLA-5100 at 635 nm. TDP1 catalytic
activity was quantified as % cleavage of 3′PY to 3′P and data are the average of three biological replicates ± STD. (G) The indicated cells were treated with
DMSO, 1 M or 5 MCPT-11 for 1.5 h and left to recover for 2 h prior to fixing, permeabilising and immunostaining with a H2AX primary antibody
(JBW301, Millipore) and a FITC-labeled secondary antibody. H2AX foci were counted for 36 cells per sample on a Nikon Eclipse e-400 microscope and
the average number of H2AX foci per cell for three independent experiments is shown ± STD. The RKO cell line and resistant clones RSC316 (H) and
RSC526 (I) as well as the DLD1 cell line and resistant clone DSC53 (J) were subjected to an irinotecan survival assay in the presence and absence of 1 M
olaparib (PARP inhibitor). The cells were pre-treated with olaparib for 1 h prior to addition of indicated amounts of CPT-11, both left in for the duration
of colony formation. The colonies were fixed, stained and counted and presented as the average surviving fraction for three independent experiments ±
STD. (K) Similarly, the RKO and RSC316 cell lines were subjected to an oxaliplatin survival assay in the presence and absence of 1 M olaparib. The
surviving fraction is shown for the average of three independent experiments ± STD.
kaline COMET assay (MACA) (22). No significant differ-
ence was observed in the levels of TOP1cc upon irinotecan
treatment for all five irinotecan-resistant RKO clones tested
compared to the parental RKO cell line (P > 0.05; t-test),
indicating no detectable change in TOP1 activity (Figure
2D). This was further confirmed by an independent assay in
which we purified irinotecan-induced TOP1cc by CsCl frac-
tionation followed by anti-TOP1 immunoblotting (Figure
2E). Upregulation of TDP1 was ruled out as a mechanism
of resistance as measured by TDP1 activity assay, which
is a more sensitive readout than immunoblotting (Figure
2F and Supplementary Figure S2C). Since TDP2, a TOP2
PDB repair factor (46), has also been shown to contribute
to TOP1 PDB repair under certain circumstances (47,15),
we compared parental and resistant cells for sensitivity to
TOP2 targeting drugs and TDP2 expression. Irinotecan-
resistant cells did not show cross-resistance to doxorubicin
or etoposide and exhibited comparable expression of TDP2
(Supplementary Figure S3A and S3B). Furthermore, in
vitro TDP1 substrate processing, which should also reveal
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TDP2 activity on TOP1 substrates, was lost in the absence
of TDP1, suggesting that TDP2 is not compensating for re-
pair in irinotecan-resistant cells (Figure 2A–2C, lower pan-
els and Supplementary Figure S1C and S1D). The key cyto-
toxic lesion generated by trapped TOP1cc and subsequent
formation of a PDB is a DNA double-strand break (DSB)
(20,48). RKO cells and five irinotecan-resistant clones dis-
played no significant difference in the average number of
H2AX foci per cell (p>0.05, t-test), a cellular marker of
DNADSBs (Figure 2G). The lack of difference was not due
to drug saturation since a lower non-saturating dose (1M)
of irinotecan also failed to reveal a difference in DSB levels.
This finding additionally implies that drug processing and
drug efflux are unlikely to account for resistance, which is
supported by the variable expression of the drug efflux fac-
tor MRP4 across multiple resistant clones (Supplementary
Figure S3C). Together, we conclude from these experiments
that a reduction of TOP1 expression/activity, an increase in
TDP1 or TDP2 expression/activity or rate of DSB forma-
tion does not account for irinotecan resistance.
We next examined whether resistance could be overcome
by the FDA approved PARP inhibitor, olaparib. Treatment
with 1Molaparib was able to restore irinotecan sensitivity
of resistant cells (Figure 2Hand 2I, and SupplementaryFig-
ure S4A and S4B) without affecting plating efficiencies or
survival in irinotecan untreated cells (Supplementary Fig-
ure S4E, S4F and S4G).Whilst the extent of sensitisation in
the resistant cells was comparable to the inherent irinotecan
sensitivity of the parental RKO cell line, olaparib similarly
sensitised the parental RKO cells to irinotecan. This sensiti-
sation was also observed in the DLD1 parental cell line and
the DLD1-derived resistant clones, DSC53 and DSC215
(Figure 2J, Supplementary Figure S4C). PARP inhibition
did not sensitise the clones to oxaliplatin, as would be ex-
pected if a PARP related resistance mechanism was shared
(Figure 2K and Supplementary Figure S4D). We conclude
from these experiments that olaparib is able to promote
irinotecan sensitivity in both parental and resistant CRC
cells and thus cannot provide a mechanism for resistance.
The ‘immunity’ of irinotecan resistant cells to TDP1 de-
pletion further confirms that changes in the TDP1/PARP1
axis cannot explain resistance.
DNA DSBs generated by CPT-based agents signal cellu-
lar G2/M arrest whilst overwhelming levels of unrepaired
DNADSBs activate apoptosis-mediated cell death (35). To
examine G2/M checkpoint we compared parental and re-
sistant clones for cell cycle profile by fluorescence-activated
cell sorting (FACS). The parental cell line and resistant
clones experienced G2/Marrest at the 24 h time point (Fig-
ure 3A and B). However, whilst the parental RKO cell line
remained fully arrested during subsequent 48 and 72 h in-
cubations with irinotecan, resistant cells were able to par-
tially overcome G2/M arrest (Figure 3B, P < 0.05 t-test).
Notably, the more resistant RSC316 cells were more able
to overcome G2/M arrest compared to the less resistant
RSC526 cell line. Furthermore, resistant clones exhibited
fewer ‘dead’ cells (sub-G1) compared to the parental cell
line (Figure 3C). These observations show that the resis-
tant clones are less able to maintain G2/M arrest com-
pared to parental cells, which may be concomitant with
a reduced ability to trigger apoptotic response following
irinotecan treatment. Consistent with this, parental and re-
sistant clones possessed an irinotecan-dependent increase
in levels of cleaved PARP1, p21, p53 phosphorylation and
cleaved caspase 3 in line with an induction of p53, however
the induction was much more pronounced in the parental
RKO cell line than resistant clones (Figure 3D). In agree-
ment with the cell cycle analysis, the apoptotic response ap-
pears to be more attenuated in the more resistant RSC316
clone compared to the less resistant RSC526 clone. Alto-
gether, these findings demonstrate that the resistant clones
possess intact cell cycle arrest and apoptotic responses fol-
lowing irinotecan treatment, however they are less able to
maintain the arrest than the parental cell line.
We next considered that the ability to overcome DSB-
mediated cell cycle arrest and to attenuate apoptotic re-
sponse could be due to increased DSB repair rates. To test
this, cells were treatedwith irinotecan andDSB repair kinet-
ics was monitored in subsequent incubations in irinotecan-
free media for 2, 4, 6, 8 and 24 h. Consistent with results
in Figure 2G, no difference in the number of H2AX foci
was observed at the 2-h time point, however, at later time
points the number of H2AX foci declined more quickly in
resistant clones compared to parentals (Figure 4A, B and
E). The increased ability of resistant clones to repair DSBs
was further confirmed by 53BP1 immunostaining as an al-
ternative marker for DSBs (Figure 4C). DSBs are repaired
by homologous recombination (HR) or non-homologous
end joining (NHEJ). The majority of breaks generated by
IR are repaired by NHEJ and since we did not observe
cross-resistance to IR (Figure 1F), we reasoned that im-
proved NHEJ is unlikely to account for the increased re-
pair rates. Consistent with this, depletion of the key NHEJ
factor KU70 did not reverse irinotecan resistance (Supple-
mentary Figure S5). Consequently, we examined if more ef-
ficient HR underlies resistance. To test this, we monitored
RAD51 foci formation and clearance as a specificmarker of
HR (49,50). Although RAD51 foci formed with similar ki-
netics and frequency during the first 2 h following irinotecan
treatment in all clones tested, the rate at which they declined
was significantly faster in resistant clones (Figure 4D and E;
P < 0.05, t-test). The rate of pRPA foci clearance was also
consistently faster in resistant clones compared to parentals
(Figure 4F). If upregulation of HR accounts for resistance
to irinotecan, one would expect cross-resistance to specific
HR targeting therapies. To test this, we treated cells with
the replication inhibitor hydroxyurea (HU) and examined
cellular response using clonogenic survival assays. Indeed,
irinotecan-resistant clones were also resistant to HU (Fig-
ure 4G). Furthermore, Rad51 foci clearance was signifi-
cantly faster following HU treatment in the resistant clones
compared to parental (Figure 4H; P< 0.05, t-test). We sub-
sequently examined two resistant clones derived from the
DLD1 parental cell line; one highly resistant DSC53 and a
slightly less resistant DSC215 clone. In striking similarity
to observations with RKO-derived resistant cells, DLD1-
derived resistant clones were able to clear RAD51 foci at
significantly faster kinetics compared to the parental DLD1
cell line (Figure 4I). Notably, the observed cross-resistance
with oxaliplatin (Figure 1H) could also be explained by
an increase in HR since oxaliplatin-mediated damage is re-
paired in part by HR (51). Together, these data demonstrate
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Figure 3. Irinotecan-resistant cells display attenuated cell cycle arrest and apoptosis following irinotecan treatment. (A) The RKO parental, RSC316 and
RSC526 resistant cells were treated continuously with 1 M or 5 M CPT-11 for 24, 48 and 72 h. Cells were stained with propidium iodide solution and
DNA content analysed by cell sorting on a FACS CANTO system. Cell cycle distribution was determined using the FCS Express 4 Flow software and
representative cell cycle charts for one of three biological replicates is shown. (B) The proportion of live cells in G2 was determined by FACS analysis
and data represent the average of three biological repeats ± SEM. (C) The average percentage of sub-G1 cells obtained by FACS analysis are graphically
depicted for three biological repeats± SEM. (D) Whole cell extract prepared from the indicated cell lines treated continuously with 5 MCPT-11 for 24, 48
and 72 h were separated by 10% SDS-PAGE and analysed by immunoblotting using anti PARP1 and cleaved PARP1 (A6.4.12, Biorad), p21 (SC417, Santa
Cruz Biotechnologies), p53 phosphorylated at serine 15 (#9284, Cell Signaling Technology), cleaved caspase 3 (E83-77, Abcam), pT68 CHK2 (#2661, Cell
Signaling Technology), p53 (DO-1, Sigma-Aldrich) and actin (A4700; Sigma-Aldrich). A representative blot for one of three repeats is shown.
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Figure 4. Improved double-strand break repair in irinotecan-resistant cells. Parental RKO and RKO-derived irinotecan-resistant RSC316 and RSC526
cells were exposed to DMSO ‘UT’ or 2 M CPT-11 for 1.5 h and left to recover in CPT-11 free media for 2, 4, 6, 8 and 24 h. Cells were subsequently
fixed and permeabilised for immunostaining with antibodies against H2AX (JBW301, Millipore) (A) or cell lysates were fractionated by SDS PAGE and
analysed by immunoblotting (B). Cells treated as in (A) were additionally immunostained with antibodies against 53BP1 (A300-272A, Bethyl Laboratories)
(C), RAD51 (H-92, Santa Cruz Biotechnologies) (D), or pRPA (A300-245A, Bethyl Laboratories, Texas, USA) (F). The number of foci per cell for 36
cells was counted manually on a Nikon Eclipse e-400 microscope and the average number of foci per cell for three independent experiments is shown ±
STD. Asterisks denote statistical significance; *P < 0.05, **P < 0.01; Student’s t-test. (E) Representative images for RAD51 and H2AX staining are
shown for the indicated cell lines and recovery timepoints. (G) RKO parental and its irinotecan-resistant derived clones were incubated with the indicated
concentrations of hydroxyrea (HU). Survival was calculated as described in Figure 1 and data are the average of three independent biological repeats ±
STD. (H) The parental RKO cell line and the RSC316 and RSC526 irinotecan resistant clones were treated in media containing DMSO ‘UT’ or 0.5 mM
HU for 1.5 h and left to recover for the indicated timepoints. Cells were fixed, permeabilised and immunostained using antibodies against RAD51 as above.
The number of foci per cell for 36 cells was counted manually and the average number of foci per cell for three independent repeats is shown± STD. (I) The
DLD1 parental cell line and DLD1 derived irinotecan-resistant DSC53 and DSC215 cells were treated with 4 M CPT-11 for 1.5 h, washed and left to
recover in CPT-11 free media for indicated timepoints. Cells were subsequently fixed, permeabilised and immunostained with antibodies against RAD51
as above. Average RAD51 foci per cell for 36 cells counted per experiment is shown for three independent biological repeats ± STD. Asterisks denote
statistical significance; *P < 0.05, **P < 0.01; Student’s t-test.
that improved HR-mediated PDB repair underpins irinote-
can resistance in CRC cells.
In addition to its canonical roles during HR, RAD51
has recently been shown to promote replication fork rever-
sal (18). Replication fork reversal can protect forks follow-
ing TOP1 poisoning in a PARP1 dependent manner (17).
Neither PARP1 depletion by siRNA nor depletion of the
RECQ1 helicase that controls fork restart/reversal restored
sensitivity to irinotecan in resistant clones, suggesting that
changes in replication fork reversal is unlikely to account
for irinotecan resistance (Supplementary Figure S6). An in-
crease in DSB repair rates should however improve the abil-
ity to restart irinotecan-arrested replication forks. To test
this, we first compared resistant and parental clones for
replication fork speed using the DNA fibre assay (52). Cells
were incubated with chlorodeoxyuridine (CldU) for 20 min
to label newly replicated DNA followed by a 30 min in-
cubation with iododeoxyuridine (IdU) (Figure 5A, inset).
Parental RKO and resistant RSC316 cells exhibited com-
parable average fork speed of 0.79 and 0.72 kb/min, respec-
tively (Figure 5A). Consistent with this, both cell lines did
not show detectable difference in the distribution of fork
rates (Figure 5B). We next compared replication fork struc-
tures by incubating cells with CldU to label newly repli-
cated DNA followed by a challenge with CPT-11 and then
incubation with iododeoxyuridine (IdU) (Figure 5C). Al-
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Figure 5. Irinotecan-resistant cells display more fork restart events but no detectable change in HR factors. (A) Parental RKO and its derivative RSC316
irinotecan-resistant cells were pulse labeled with CldU for 20 min to label newly replicated DNA, followed by IdU for 30 min to measure replication fork
speed. DNA fibres were spread on superfrost slides, fixed, and stored at 4◦C. DNA fibers were subjected to acid denaturation using 2.5 M HCl. Slides
were then stained with a mixture of rat anti-BrdU (clone BU1/75, Serotec) targeting CldU and mouse anti-BrdU (clone B44; Becton Dickinson) targeting
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though parental and resistant cells showed similar frequen-
cies of stalled and on-going forks (Figure 5D), treatment
with irinotecan resulted in a significant difference in fork
structures. Whereas parental RKO cells possessed ∼50%
stalled forks and∼35% fork restarts, resistant RSC316 cells
possessed ∼25% stalled forks and 60% fork restarts (Figure
5E). The improved rate of fork restart is likely related to
faster repair rates of DSBs by HR as suggested by a hyper-
recombination phenotype (Supplementary Figure S7). We
next examined if the observed increase in repair rate is
driven by increased activity of the HR machinery per se.
Together with key HR repair factors, a number of addi-
tional nucleases have been implicated during HR-mediated
repair of CPT induced DNA damage such as MUS81 and
XPF/SLX4 (6). Using immunoblotting, microarray and
quantitative PCR, we observed no upregulation in the level
of these nucleases nor in ATM signalling or the key HR re-
pair factors CtIP, Rad51, BRCA1 and RPA (Figure 5F–H
and Supplementary Figure S8). Depletion of the HR re-
section enzyme CtIP sensitised cells to irinotecan but did
not selectively restore sensitivity in irinotecan-resistant cells
(Supplementary Figure S9). Furthermore, mRNA profiling
by microarray of parental and resistant cells failed to detect
any significant change in the transcripts of genes known,
or predicted, to participate in TOP1 mediated PDB repair
(Supplementary Figure S10).
We next considered the possibility that changes in the
chromatin landscape might underlie the improved PDB re-
pair rate in resistant cells. Recent studies have highlighted
the importance of chromatin modification in modulating
the recruitment of DNA repair factors to damage sites. For
instance, histoneH4K16 acetylation appears to regulate the
accumulation of the 53BP1 repair factor at DNA DSBs,
thereby controlling repair dynamics (53). Whilst we found
no detectable changes in PDB repair factors, we did how-
ever note faster but transient accumulation of the 53BP1
repair factor in response to irinotecan in the resistant clones
(Figure 4C). This observation prompted us to compare
parental and resistant cells for levels of H4K16 acetyla-
tion. RKO and RSC316 cells were pre-treated with the hi-
stone deacetylase (HDAC) inhibitor trichostatin A (TSA)
followed by irinotecan treatment and recovery. Cell extracts
were analyzed by western blotting using antibodies against
H4K16Ac as well as other histone acetylationmodifications
including H3K14Ac, H3K56Ac and H3K9Ac (Figure 6A).
Whilst no difference was observed in H3K14Ac, H3K56Ac
and H3K9Ac between parental and resistant cells, the lat-
ter possessed remarkably lower levels of H4K16Ac, high-
lighting a reduction of H4K16Ac steady state levels (Fig-
ure 6B). This appears to be common across multiple resis-
tant clones (Supplementary Figure S11A and S11B). These
observations suggest that the turnover rate of H4K16Ac is
perturbed in irinotecan-resistant cells, potentially explain-
ing the increased 53BP1 accumulation to damage sites. If
this is true, one would predict that increasing the level of
H4K16Ac by pre-treatment with TSA could restore nor-
mal levels of 53BP1 accumulation. To test this, we carried
out 53BP1 immunostaining on cells treated with irinote-
can in the presence of TSA to enrich for the H4K16Ac
modification. Indeed, the attempts to re-adjust the levels
of H4K16Ac using TSA slowed 53BP1 accumulation to
damage sites in both the RSC316 and RSC526 resistant
clones, but not parental CRC cells, without affecting the ini-
tial number of H2AX foci (Figure 6C, Figures S11C and
S12B).
We next examined if restoring H4K16Ac would impact
the DSB repair rate observed in irinotecan resistant cells.
TSA treatment suppressed the faster rate of irinotecan-
induced DSB repair in irinotecan resistant but not parental
cells (Figure 6D). Following 8 h recovery, TSA had no
significant impact on the number of H2AX foci per cell
in parental cells whereas an increase was observed in the
RSC316 resistant cells from ∼7 to 20 foci per cell, which
is similar to the number observed in parental cells. A simi-
lar result was obtained for the RSC526 clone (Supplemen-
tary Figure S12A). TSA had no detectable impact on the
rate of RAD51 foci clearance in RKO parental cells but
it significantly suppressed the faster clearance rate in the
RSC316 resistant cells, bringing Rad51 foci per cell at 6 h
recovery time point to a level similar to that observed in
parental cells (Figure 6E). Consistently, TSA was also able
to suppress the improved ability to re-start arrested forks in
irinotecan resistant cells (Figure 6F). To further show that
the phenotypes observed in our resistant clones is related
to the slower turnover of H4K16Ac, we attempted to cre-
ate irinotecan resistance in the parental RKO cell line by
reducing H4K16Ac through depletion of one of the dam-
age response H4K16 histone acetyl transferases (HATs),
TIP60.Depletion of Tip60moderately reduced the turnover
of H4K16Ac in RKO cells (Supplementary Figure S11D).
Clonogenic survival assays and growth assays show that
Tip60 depletion partially promotes irinotecan resistance in
the parentalRKOcell line (SupplementaryFigure S11E and
S11F). Tip60 depletion consistently led to a mild increase
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
IdU. DNA fibres were visualised using donkey anti-rat Alexafluor 488 and goat anti-mouse Alexafluor 555 secondary antibodies on an Olympus BX53
fluorescence upright microscope. Lengths of the fibres were measured, and speeds of the forks were determined using speed = length (kb)/time (min).
Data are the average of three biological replicates ± SEM. Inset: Schematic depicting the DNA labelling procedure. (B) The average distribution of fork
speeds is depicted from three biological replicates ± SEM. (C) A schematic showing the labelling procedure and the different replication fork structures;
green-red signals represent on-going forks, green only represent stalled forks, and red only represent new origin firing. (D and E) Parental RKO and its
derivative irinotecan-resistant cells were pulse labelled with CldU for 10 min to label newly replicated DNA, followed by treatment with DMSO ‘-CPT-11’
(D) or 50 MCPT-11 ‘+CPT-11’ (E) for 30 min, followed by 1 h incubation with IdU. DNA fibres were spread on superfrost slides, fixed, and processed as
described in ‘A’. At least 238 fork structures were counted per sample and the average number of stalled forks, fork restart ‘ongoing forks’, and new origin
firing was quantified from three biological replicates ± SEM. Asterisks denote statistical significance; *P < 0.05, Student’s t-test. (F and G) Cell lysates
from the indicated cell lines were fractionated by SDS-PAGE and analysed by immunoblotting. (H) Parental and resistant cells were exposed to CPT and
mRNA extracted using RNeasy mini RNA purification kit. mRNA was subjected to microarray analysis using a HumanHT-12 v4 WG-GX Beadchip on
the Illumina BeadArray system. Expression changes of HR genes in resistant cells were presented as fold change relative to the parental RKO cells. Data
are the average of two independent biological repeats ± range.
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Figure 6. Deregulation of histone H4K16 acetylation in resistant cells promotes DNA repair and highlights the utility of HDAC inhibitors for the reversal
of irinotecan resistance. (A) RKO and RSC316 cells were pre-treated with 1 M TSA for 2 h, followed by treatment with 2 M CPT-11 for 1.5 h and
recovery for 2 h. Prepared whole cell extracts were separated by 15% SDS-PAGE and analyzed by immunoblotting using antibodies against H3K56Ac,
H3K14Ac, H3K9Ac, H4K16Ac and tubulin. Representative blots for one of three repeats are shown. LE; low exposure, HE; high exposure. (B) Relative
H4K16Ac expression levels were quantified from the TSA treated samples from 3 biological replicates, a representative of which is shown in (A) using
ImageJ and subsequent normalizing to tubulin levels. Calculations from three replicates ± STD is shown. (C) RKO and RSC316 cells were pre-treated
with 1 M TSA for 2 h, followed by treatment with 2 M CPT-11 for 1.5 h and recovery for 1 or 2 h. Cells were fixed, permeabilised and analysed by
immunostaining for 53BP1. The number of foci per cell for 36 cells was counted manually on a Nikon Eclipse e-400 microscope and the average number
of foci per cell for three independent experiments is shown ± STD. Cells were similarly treated with TSA and CPT-11 and allowed to recover for indicated
timepoints for analysis of H2AX (D) and Rad51 (E) foci per cell, measured as above. Results show the average of three biological replicates ± STD.
RKO and RSC316 cells were pre-treated with 500 nM TSA (F) or 250 nM Panobinostat (LBH-589) (H) for 30 min, pulse labelled with CldU for 10 min
to label newly replicated DNA, followed by treatment with 50 M CPT-11 for 30 min, followed by 1 h incubation with IdU. DNA fibres were spread on
superfrost slides, fixed, and processed. At least 50 fork structures were counted per sample and the average percentage stalled forks was quantified from
three biological replicates± SEM. Cells were treated with 10 nM of TSA (G) or 2.6 nM Panobinostat (LBH-589) (I), followed by exposure to the indicated
concentrations of CPT-11 for the duration of colony formation. Survival was calculated from three biological replicates± STD. Asterisks denote statistical
significance; *P < 0.05, **P < 0.01; Student’s t-test.
in 53BP1 accumulation and faster H2AX foci clearance
(Supplementary Figure S11G and S11H).
Since TSA treatment was able to efficiently reverse mul-
tiple resistance-associated phenotypes described above, we
next examined if TSA could selectively sensitise irinotecan-
resistant cells and thus reverse drug resistance. An opti-
mal TSA dose (10 or 50 nM) that does not affect survival
in the absence of irinotecan treatment was selected for co-
treatment clonogenic survival assays (Supplementary Fig-
ure S13). RKO and RSC316 cells were pre-treated with 10
nM TSA and irinotecan sensitivity was measured by clono-
genic survival assays. We observed a stark reversal of re-
sistance, particularly at lower irinotecan doses in resistant
but not parental cells (Figure 6G). TSA furthermore sensi-
tised multiple irinotecan-resistant cells to irinotecan (Sup-
plementary Figure S14). Further consolidating this finding,
treatment with an alternative HDAC inhibitor, Panobinos-
tat (LBH589) also led to increased fork stalling (Figure 6H)
and irinotecan sensitivity (Figure 6I). Finally, we examined
whether changes in chromatin acetylation are a hallmark
of tumour formation and progression in colorectal cancer.
Normal human colon tissue, primary and metastatic CRC
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tissues were subjected to immunohistochemistry (IHC) us-
ing H4K16ac antibodies. CRC tissues displayed a signifi-
cant reduction in H4K16ac staining with a progressive de-
cline in % positive cells as the tumour advanced from grade
I, II to III (Figure 7). We conclude from these experiments
that alterations in the chromatin acetylation landscape are
hallmarks of CRC, underlying irinotecan resistance, and
subsequent perturbation using HDAC inhibitors canmech-
anistically reverse resistance.
DISCUSSION
The response to the chemotherapy agent irinotecan during
colorectal cancer treatment is in most cases lost due to on-
set of drug resistance.Mechanisms promoting resistance are
poorly characterized and a clearer understanding will allow
for the identification of suitable treatment alternatives. We
report that the mechanism of resistance onset is not due to
deregulation of TOP1 or TDP1 but due to improved DNA
DSB repair as observed in multiple independently gener-
ated irinotecan-resistant clones. The increased DNA DSB
repair rate was due to changes in the chromatin acetylation
landscape, in particular H4K16ac, and subsequent inhibi-
tion of histone deacetylases selectively sensitized irinotecan-
resistant but not parental cells.
We generated irinotecan resistant clones from two well-
studied colorectal cancer cell lines, RKO and DLD1. This
approach provided an invaluable control, allowing for di-
rect comparison of changes that have occurred as a result
of continuous irinotecan exposure. Such controls are invari-
ably much more difficult to achieve when directly study-
ing patient samples. Using these research tools, we found
that TDP1 upregulation or TOP1 loss was at the very least
ruled out as common mechanisms of resistance. Resistant
clones accumulated similar levels of toxic DNADSBs upon
irinotecan treatment compared to the parental cell line,
which further rules out differences in DNA SSB repair ca-
pacity, drug delivery/efflux, and the ability of irinotecan to
cause damage as possible mechanisms of resistance. Resis-
tant clones were still able to trigger cell cycle arrest in re-
sponse to irinotecan treatment but they appeared to escape
this arrest more quickly, subsequently sparing cell death by
apoptosis. This difference correlated well with the increased
ability of the resistant clones to clear DSBs as measured by
faster rates of clearance of the canonical DSB repair factors
RAD51 and pRPA (52). Cross-resistancewas observedwith
hydroxyurea and oxaliplatin treatments ruling out hyper-
elimination of drugs, as a mechanism of resistance, by drug
efflux pumps for example, given that this action is likely to
be specific to drug type. The similar number of irinotecan-
induced DSBs and TOP1cc, measured by two independent
techniques, further confirm that irinotecan is still capable of
inflicting comparable damage in both parental and resistant
clones.
Whilst we observed an increase in DNA DSB repair, we
saw no changes in the levels of DSB repair factors and
associated endonucleases, using immunoblotting and mi-
croarray profiling.Wewere inclined therefore to understand
whether events leading up to damage recognition and repair
could contribute to the onset of irinotecan resistance. A fine
balance of histone modifications (methylation and acetyla-
tion) is known to affect DNA repair dynamics (54). For in-
stance, 53BP1 is recruited to damage sites by direct interac-
tion of its tandem Tudor repeats with histone H4K20me1
and H4K20me2 (55–57). Tip60-mediated histone H4K16
acetylation was conversely shown to reduce the binding of
53BP1 to methylated histones, thus regulating the competi-
tive recruitment of 53BP1 and BRCA1 to DNADSBs (53).
This impacts on the extent of DNA end-resection achieved
and subsequently the repair pathway utilised forDSB repair
(53,58–60). In multiple resistant clones, we observed faster
but transient accumulation of 53BP1 at damage sites and
subsequently identified a reduction in the level of H4K16
acetylation. Treatment with the HDAC inhibitor TSA re-
sults in enrichment of H4K16Ac, re-adjusts the rate of
53BP1 accumulation, increases fork stalling and ultimately
selectively sensitises irinotecan-resistant clones to irinote-
can (Figure 6). In contrast, we observed no irinotecan sensi-
tisation in the TSA treated parental RKO cell line. The lack
of sensitisation in the parental cell line may be TSA dose
dependent, or it may reflect differences in repair pathway
choices between the RKO parental cell line and the resis-
tant clones.
How these observed differences ultimately promote
irinotecan resistance is not entirely clear. What is clear is
that cross-resistance is shared with treatments that rely at
least in part on the HR pathway for repair, i.e. oxaliplatin
and HU. It is possible that loss of H4K16Ac in response
to prolonged irinotecan treatment targets breaks normally
destined for HR repair towards NHEJ by recruiting 53BP1
to the break site more readily. Such sharing of repair work-
load between two repair pathways would lessen the bur-
den on the HR machinery, which is already improved as
shown by rapid RAD51 foci clearance. Thus, it could pro-
vide a feedbackmechanism throughwhich the evolving can-
cer cells attempt to improve both DSB repair pathways to
combat irinotecan induced DNA damage.
We note that HDAC inhibitor treatment will affect the
acetylation status of a wide range of targets, thus it is pos-
sible that the acetylated target responsible for mediating
changes in DSB repair kinetics is not exclusively restricted
to H4K16 (61,62). Notably, suppression of histone deacety-
lation using other inhibitors of HDACs also sensitizes re-
sistant, but not parental, cells to irinotecan. These find-
ings are consistent with a model in which alterations in
H4K16ac impact DSB repair rate and, as a result, cellular
survival following irinotecan. In support of the involvement
of H4K16Ac regulation as a resistance mechanism, we fur-
ther show that loss of Tip60 in the parental RKO cell line re-
duces H4K16Ac and promotes partial resistance to irinote-
can. The partial resistance achieved implies that resistance
may be triggered through altered regulation of both acetyla-
tion and deacetylation dynamics. Whilst we observed stark
reversal of resistance using TSA treatment, we did not ob-
serve complete reversal suggesting that other mechanisms
of resistancemay exist alongside deregulatedH4K16Ac. In-
deed, we identified two subpopulations of resistant clones
derived from theRKOparental cell line, both of which share
deregulation of H4K16Ac in response to irinotecan treat-
ment. It is therefore conceivable that themore resistant pop-
ulation possesses additional mechanisms of resistance and
that changes in H4K16ac is a novel, but not the only, mech-
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Figure 7. Hypoacetylation of H4K16 is a hallmark of CRC tissues. (A) Normal, primary andmetastatic CRC tissues were subjected to immunohistochemi-
cal analyses usingH4K16ac antibodies (Abcam, catalogue number ab109463) and a Vectastain Elite kit was used for secondary antibody andAvidin-Biotin
Complex (ABC) conjugation. Staining was considered positive when a brown nuclear reaction was observed. A representative image from each condition
is shown. Control; IHC was conducted without the incubation of primary antibodies. (B). IHC staining was quantified using ImageJ software (version
1.49, NIH, USA) and presented as average ± SEM. A paired Student’s t-test was used to determine the statistical significance between normal, primary
and metastatic carcinoma. Asterisks denote P < 0.05. CRC tissues with the indicated grades were subjected to IHC analyses as described above and a
representative image is shown (C) and % positive H4K16ac was quantified and presented as average ± SEM (D). (E) A model for chromatin acetylation
driven irinotecan resistance. In normal irinotecan-responsive cells, appropriate acetylation dynamics of H4K16 results in normal recruitment and retention
of 53BP1, resulting in increased fork stalling and DSB persistence, ultimately causing cell death. Failure to maintain the appropriate dynamics of H4K16
acetylation results in increased accumulation of 53BP1, reduced fork stalling and ultimately cell survival. Treatment with histone deacetylase inhibitors
can selectively sensitise irinotecan resistant cells, thereby overcoming drug resistance.
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anism of resistance. Importantly, HDAC inhibitors are cur-
rently FDA approved for clinical use withmultiple agents in
clinical trials, which could be tested for the targeted treat-
ment of irinotecan-resistant CRC.
In agreement with our main findings, we were able to
rule out other possible mechanisms of resistance. Whilst we
observed remarkable irinotecan sensitization using PARP
inhibitor treatment, we observed a similar extent of sen-
sitization in parental cell lines. It has been reported that
TOP1cc triggers replication fork reversal that is controlled
by PARP1 and the RECQ1 helicase (16,17). This occurs
in an effort to avoid direct collision of the replication ma-
chinery with the TOP1-PDB and therefore DSB formation,
thus allowing more time for repair of TOP1-PDBs most
likely via the SSB repair pathway. Whilst PARP1 deple-
tion had mild impact on irinotecan sensitivity, it did not
restore sensitivity of irinotecan-resistant clones, suggesting
that PARP1-regulated fork reversal is unlikely to contribute
to resistance. In support of this notion, there was no dif-
ference in the initial numbers of DSBs following irinote-
can treatment. Interestingly, PARP1 is known to promote
TDP1-dependent repair of trapped TOP1-cc in preparation
for fork restart (12,14). Our data further argue against a
role for TDP1/PARP1 axis as a mechanism of resistance
since TDP1 depletion was similarly not able to reverse re-
sistance. In contrast to PARP1 depletion, poisoning theHR
machinery by PARP inhibition sensitized both parental and
irinotecan resistant CRC cells to irinotecan, which is consis-
tent with the published literature in other cancer types (63).
Thus, PARP inhibition interferes with the normal process-
ing of irinotecan-mediated damage but deregulated PARP
activity is unlikely to promote irinotecan resistance.
These findings have important clinical implications that
can now be explored. For instance, a clinical study exam-
ining the efficacy of PARP or HDAC inhibitors in both
irinotecan responsive and non-responsive patients should
be of major interest, particularly since these inhibitors are
already FDA-approved. Interestingly and in support of our
findings, it has been reported that loss of monoacetylated
forms of histone H4 appears early and accumulates dur-
ing the tumorigenic process in skin cancer (64). The losses
occurred predominantly at the acetylated Lys16 of histone
H4. Here, we also report that changes in chromatin acety-
lation in patient derived tissues are a hallmark of colorectal
cancer initiation and progression (Figure 7). It will now be
interesting to examine if loss of H4K16ac is a hallmark of
irinotecan resistance in CRC tissues, using xenograft mod-
els or clinical samples, in follow-up studies. Finally, our
findings suggest that irinotecan resistant CRC should not be
treated alternatively with an oxaliplatin-based regime (such
as FOLFOX) since cross-resistance is apparent. However,
they are unlikely to generate additional resistance to 5-FU
and radiation therapies since cross-resistance was not ob-
served.
In summary, we identify changes in histone acetylation
in irinotecan resistant colorectal cancer and further reveal
inhibitors of HDACs as promising means to overcome re-
sistance. We suggest that more attention should be given to
epigenetic changes such as acetylation when considering re-
sistance to TOP1 targeting therapies.
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